• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13D filed by Know Labs Inc.

    10/25/23 7:27:11 PM ET
    $KNW
    Industrial Machinery/Components
    Industrials
    Get the next $KNW alert in real time by email
    SC 13D 1 ea187306-13dbaszucki_know.htm SCHEDULE 13D

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    SCHEDULE 13D

    Under the Securities Exchange Act of 1934

     

    (Amendment No. 2 to Schedule 13G)

     
    KNOW LABS, INC.
     
    (Name of Issuer)
     
    Common Stock, par value $0.001 per share
     
    (Title of Class of Securities)
     
    499238103
     
    (CUSIP Number)
     
    Todd Baszucki  
    395 Del Monte Center, #306
    Monterey, CA 93940
    TEL: 831-402-5699
     
    (Name, Address and Telephone Number of Person Authorized to
    Receive Notices and Communications)
     
    October 16, 2023
     
    (Date of Event Which Requires Filing of this Statement)

     

    If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box ☒

     

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

     

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     

     

     

    CUSIP No. 499238103

     

    1. Name of Reporting Persons.
      Todd Baszucki
       
      I.R.S. Identification Nos. of above persons (entities only).
       
    2. Check the Appropriate Box if a Member of a Group (See Instructions)
       
      (a) ☐
      (b) ☐
       
    3. SEC Use Only
       
       
    4. Source of Funds (See Instructions):     PF
       
       
    5. Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e)     ☐
       
       
    6. Citizenship or Place of Organization:     USA
       
       

     

     

    Number of Shares
    Beneficially
    Owned by Each
    Reporting Person
    With:

    7. Sole Voting Power     17,200,000

     
     
    8. Shared Voting Power     0
     
     
    9. Sole Dispositive Power     17,200,000
     
     
    10. Shared Dispositive Power     0
     
     

    11. Aggregate Amount Beneficially Owned by Each Reporting Person     17,200,000
       
       
    12. Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)      ☒
       
      This excludes warrants for the purchase of 1,000,000 shares of common stock.
    13. Percent of Class Represented by Amount in Row (9)     21.4% 1
       
       
    14. Type of Reporting Person (See Instructions)     IN
       
       

     

     

    1Based   on 80,358,463 shares of Common Stock outstanding as of October 16, 2023, as confirmed by the Issuer.

     

    - 2 -

     

     

    Item 1. Security and Issuer

     

    Todd Baszucki (the “Reporting Person”) previously filed a Schedule 13G on April 12, 2022, as amended February 14, 2023 (the “Schedule 13G”). This Schedule 13D (this “Schedule 13D”) relates to the common stock (the “Common Stock”) of Know Labs, Inc. fka Visualant, Incorporated, a Nevada corporation (the “Issuer” or “Registrant”), and amends the Schedule 13G.  The address of the principal executive offices of the Issuer is 500 Union St, Suite 810, Seattle, WA 98101, its telephone number is (206)903-1351

     

    Item 2. Identity and Background

     

    (a)This Schedule 13D is being filed by Todd Baszucki (the “Reporting Person”).

     

    (b)The principal business address for the Reporting Person is 395 Del Monte Center, #306
    Monterey, CA 93940

     

    (c)The principal occupation of the Reporting Person is a self employed, private investor, the business address of which is 395 Del Monte Center, #306 Monterey, CA 93940.

     

    (d)The Reporting Person has not been convicted in a criminal proceeding (excluding traffic violations or similar misdemeanors) during the last five years.

     

    (e)During the last five years, the Reporting Person has not been a party to a civil proceeding of a judicial or administrative body of competent jurisdiction and as a result of such proceeding was or is subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violation with respect to such laws.

     

    (f)The Reporting Person is a citizen of the United States.

     

    Item 3. Source and Amount of Funds or Other Consideration

     

    The Reporting Person used cash to make the purchases of Common Stock.

     

    Item 4. Purpose of Transaction

     

    The Common Stock was acquired for, and are being held for, investment purposes. Depending on the factors discussed herein, the Reporting Person may, from time to time, acquire additional shares of Common Stock and/or retain and/or sell all or a portion of the shares of Common Stock held by the Reporting Person in the open market or in privately negotiated transactions, and/or may distribute the Common Stock held by the Reporting Person to other entities. Any actions the Reporting Person might undertake will be dependent upon the Reporting Person’s review of numerous factors, including, among other things, the price levels of the Common Stock, general market and economic conditions, ongoing evaluation of the Issuer’s business, financial condition, operations and prospects, the relative attractiveness of alternative business and investment opportunities, investor’s need for liquidity, and other future developments. 

     

    The Reporting Person has no present intention to sell any shares of Common Stock, although any Reporting Person could determine from time to time, based upon the same factors listed above for purchases, to sell some or all of the shares of Common Stock held by such Reporting Person.

     

    The Reporting Person does not have any plans or intentions that would result in any of the actions or transactions described in clauses (a)through (j) of Item 4 of Schedule 13D, except as previously disclosed in this Schedule 13D, or as set forth above.

     

    Item 5. Interest in Securities of the Issuer

     

    (a) As of October 16, 2023, Mr. Baszucki beneficially owns 17,200,000 shares of Common Stock individually. This total includes all shares of common stock acquired in private placements through September 30, 2023, open market acquisitions and dispositions of shares of common stock through September 30, 2023, and excludes warrants for the purchase of 1,000,000 shares of common stock.

     

    Mr. Baszucki beneficially owns 21.4% of the Common Stock outstanding, based on total shares of Common Stock outstanding as of Octoober 16, 2023 of 80,358,463 shares of Common Stock, as confirmed by the Issuer.

     

    (b) As of October 16, 2023, Mr. Baszucki had sole voting power and sole dispositive power with respect to 17,200,000 common stock shares, excluding an additional 1,000,000 shares of Common Stock assuming exercise of all warrants to purchase common stock (which have been excluded from the Reporting Person’s total voting power).

     

    (c) Within the 60 days prior to the filing of this Schedule 13D, Mr. Baszucki acquired /disposed of the following securities of the Issuer:

     

    - 3 -

     

     

    On August 25, 2023, Mr. Baszucki purchased 10,000 shares of common stock at a purchase price of $0.6799 per shares through open market purchases.

     

    On September 7, 2023, Mr. Baszucki purchased 20,000 shares of common stock at a purchase price of $0.6299 per share through open market purchases.

     

    September 15, 2023, Mr. Baszucki purchased 245,545 shares of common stock at a purchase price of $0.5675 per share through open market purchases.

     

    On September 29, 2023, Mr. Baszucki purchased 14,000,000 shares of common stock at $0.25 per share pursuant to Issuer’s Registered Offering on Form S-1 declared effective September 26, 2023 (Registration No. 333-274350).

     

    September 25, 2023, Mr. Baszucki sold 96,517 shares of common stock at a sales price of $0.4538 per share through open market sales.

     

    September 26, 2023, Mr. Baszucki sold 200,000 shares of common stock at a sales price of $0.3607 per share through open market sales.

     

    September 27, 2023, Mr. Baszucki sold 249,300 shares of common stock at a sales price of $0.2360 per share through open market sales.

     

    September 28, 2023, Mr. Baszucki sold 317,891 shares of common stock at a sales price of $0.2406 per share through open market sales.

     

    (d) Not applicable.

     

    (e) Not applicable.

     

    Item 6. Contracts, Arrangements, Understandings or Relationships with Respect to Securities of the Issuer

     

    Except as described herein, the Reporting Person nor any other person referred to in Item 2 herein, has any contract, arrangements understandings or relationship (legal or otherwise) with any person with respect to any securities of the Issuer, including but not limited to the transfer or voting of any of the securities, finder’s fees, joint ventures, loan or option arrangements, puts or calls, guarantees of profits, division of profits or losses, or the giving or withholding of proxies.

     

    Item 7. Material to Be Filed as Exhibits

     

    None.

     

    - 4 -

     

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Date: October 25, 2023 By: /s/ Todd Baszucki
        Name: Todd Baszucki

     

     

    - 5 -

     

     

    Get the next $KNW alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $KNW

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $KNW
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Director Jenkinson Linda

    4 - USBC, Inc. (0001074828) (Issuer)

    8/15/25 9:37:58 PM ET
    $KNW
    Industrial Machinery/Components
    Industrials

    SEC Form 3 filed by new insider Jenkinson Linda

    3 - USBC, Inc. (0001074828) (Issuer)

    8/15/25 9:30:18 PM ET
    $KNW
    Industrial Machinery/Components
    Industrials

    SEC Form 4 filed by Chief Operating Officer Chapman Kirk

    4 - USBC, Inc. (0001074828) (Issuer)

    8/15/25 9:02:09 PM ET
    $KNW
    Industrial Machinery/Components
    Industrials

    $KNW
    SEC Filings

    View All

    SEC Form DEF 14A filed by Know Labs Inc.

    DEF 14A - USBC, Inc. (0001074828) (Filer)

    8/26/25 3:24:34 PM ET
    $KNW
    Industrial Machinery/Components
    Industrials

    SEC Form D filed by Know Labs Inc.

    D - USBC, Inc. (0001074828) (Filer)

    8/21/25 4:53:44 PM ET
    $KNW
    Industrial Machinery/Components
    Industrials

    Know Labs Inc. filed SEC Form 8-K: Leadership Update, Other Events, Financial Statements and Exhibits

    8-K - USBC, Inc. (0001074828) (Filer)

    8/15/25 8:31:15 AM ET
    $KNW
    Industrial Machinery/Components
    Industrials

    $KNW
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Know Labs, Inc. Announces Adjournment of Special Meeting of Stockholders

    Know Labs, Inc. (NYSE American: KNW ("Know Labs" or the "Company"), a technology innovator specializing in non-invasive health monitoring solutions, today announced that it has adjourned its Special Meeting of Stockholders (the "Special Meeting") scheduled for July 24, 2025 in order to provide stockholders additional time to vote on all proposals described in the Company's definitive proxy statement for the Special Meeting, filed with the Securities and Exchange Commission on June 30, 2025. The Special Meeting will be reconvened at 1:30 p.m. Pacific Time on Thursday, July 31, 2025 at the following url: www.virtualshareholdermeeting.com/KNW2025SM. The record date for the reconvened Special

    7/24/25 5:00:00 PM ET
    $KNW
    Industrial Machinery/Components
    Industrials

    Know Labs Reminds its Stockholders to Vote Ahead of the Special Meeting on July 24

    Know Labs, Inc. (NYSE:KNW) ("Know Labs" or the "Company"), a technology innovator specializing in non-invasive health monitoring solutions, today issued a reminder to its stockholders to vote ahead of the Special Meeting of Stockholders (the "Special Meeting") to be held virtually on Thursday, July 24, 2025 at 1:30 p.m. pacific time. The methods for voting and submitting proxies are described in the previously distributed proxy materials for the Special Meeting. The Company's Board of Directors encourages any stockholders as of the record date of June 20, 2025, who have not yet voted their shares for the Special Meeting, to cast their vote "For" each proposal, now. You may vote: over

    7/22/25 4:47:00 PM ET
    $KNW
    Industrial Machinery/Components
    Industrials

    Greg Kidd to Acquire Controlling Interest in Know Labs and Introduce Bitcoin Treasury Strategy

    Know Labs, Inc. (NYSE American: KNW ("Know Labs" or the "Company"), a technology innovator specializing in non-invasive health monitoring solutions, today announced that it has entered into an agreement with Goldeneye 1995 LLC ("Buyer"), an affiliate of fintech investor, entrepreneur, and former Ripple Chief Risk Officer, Greg Kidd, to acquire a controlling interest in the Company. Upon the closing of the transaction, Mr. Kidd will become Chief Executive Officer and Chairman of the Board of Directors of the Company. Under the terms of the agreement, the Buyer will acquire that number of shares of the Company's common stock obtained by dividing (i) the sum of 1,000 Bitcoin and a cash sum t

    6/6/25 9:00:00 AM ET
    $KNW
    Industrial Machinery/Components
    Industrials

    $KNW
    Leadership Updates

    Live Leadership Updates

    View All

    Know Labs Appoints Chris Somogyi as President, International

    Somogyi to lead Know Labs' "Skunkworks" Program and drive global revenues. Know Labs, Inc. (NYSE:KNW), an emerging leader in non-invasive medical diagnostic technology, today announced the appointment of Chris Somogyi as President, International. With over 40 years of experience in commercializing innovation across related industries, Somogyi brings a wealth of expertise to lead the Company's "Skunkworks" Program and global patent licensing efforts. In his role, Somogyi will focus on identifying new applications of Know Labs' extensive intellectual property (IP) portfolio consisting of over 300 patents issued, pending and in-process and covering more than 100 medical and non-medical app

    5/16/24 9:00:00 AM ET
    $KNW
    Industrial Machinery/Components
    Industrials

    Know Labs Expands Medical and Scientific Advisory Board

    New Members Bring Extensive Clinical Diabetes Management and FDA Expertise Know Labs, Inc. (NYSE:KNW), an emerging developer of non-invasive medical diagnostic technology, today announced the appointment of four new members to the Company's Medical and Scientific Advisory Board. The new additions to the Advisory Board are Jeff Hitchcock, Karmeen Kulkarni, Dr. Meng Tan and Dr. Satish Garg. They bring to the board extensive experience in clinical diabetes management, including the advancement of new technologies and innovation in medical diagnostics. The Medical and Scientific Advisory Board is chaired by Know Labs' Chief Medical Officer, Dr. James H. "Andy" Anderson. The Advisory Board p

    12/14/23 9:00:00 AM ET
    $KNW
    Industrial Machinery/Components
    Industrials

    Know Labs Expands Board of Directors

    Appoints Three New Directors with Deep Sector Expertise Know Labs, Inc. (NYSE:KNW), an emerging developer of non-invasive medical diagnostic technology, today announced the appointment of three new members to the Company's Board of Directors. These appointments increase the number of Directors to seven. Each new Director brings to the board extensive sector-relevant experience with deep knowledge of the science and the marketplace that is the focus of Know Labs. The new appointees are John Cronin, Larry Ellingson and Tim Londergan. John Cronin is the founder and CEO of ipCapital Group, Inc., a leading global advisory company on intellectual property strategy and monetization. Cronin beg

    11/8/23 9:00:00 AM ET
    $KNW
    Industrial Machinery/Components
    Industrials

    $KNW
    Financials

    Live finance-specific insights

    View All

    Know Labs, Inc. Reports Third Quarter FY2023 Results

    Know Labs, Inc. (NYSE:KNW), an emerging developer of non-invasive medical diagnostic technology, today reported financial results for the third quarter ended June 30, 2023. Financial Highlights: Know Labs reported a net loss of $3.59 million dollars in the third quarter of 2023, compared to a net loss of $3.03 million dollars in the year-ago period, which translates to Earnings Per Share of a loss of $0.07, unchanged from the year ago period of a loss of $0.07 before preferred stock dividends. Recorded a non-cash charge to earnings of $4.96 million related to the fair market value of dividends on the Company's Series C and D preferred stock, that were either paid or accrued in share

    8/14/23 4:15:00 PM ET
    $KNW
    Industrial Machinery/Components
    Industrials

    Know Labs, Inc. Reports Second Quarter FY2023 Results

    Know Labs, Inc. (NYSE:KNW), an emerging developer of non-invasive medical diagnostic technology, today reported financial results for the second quarter ended March 31, 2023. Financial Highlights: Know Labs reported a net loss of $4.93 million dollars in the second quarter of 2023, compared to a net loss of $6.14 million dollars in the year-ago period, which translates to Earnings Per Share of a loss of $0.10, an improvement over the year ago period of a loss of $0.16. Research and development expense for the second quarter was $2.56 million dollars as compared to $1.25 million dollars in 2022. The increase in R&D expense was related to staff increases in engineering, third party te

    5/15/23 4:05:00 PM ET
    $KNW
    Industrial Machinery/Components
    Industrials

    Know Labs, Inc. Reports First Quarter 2023 Results

    Know Labs, Inc. (NYSE:KNW), an emerging developer of non-invasive medical diagnostic technology, today reported financial results for the first quarter ended December 31, 2022. Financial Highlights: Know Labs reported a net loss of $3.82 million in the first quarter of 2023, compared to a net loss of $5.36 million in the first quarter of 2022, which translates to Earnings Per Share of a loss of $0.08 versus a loss of $0.15 in the year ago period. Research and development expense for the first quarter ended December 31, 2022, was $1.74 million as compared to $886,000 in the same year ago period. The increase in R&D expense was related to staff increases in engineering, third party techn

    2/14/23 4:00:00 PM ET
    $KNW
    Industrial Machinery/Components
    Industrials

    $KNW
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13D/A filed by Know Labs Inc. (Amendment)

    SC 13D/A - KNOW LABS, INC. (0001074828) (Subject)

    6/3/24 2:11:39 PM ET
    $KNW
    Industrial Machinery/Components
    Industrials

    SEC Form SC 13D filed by Know Labs Inc.

    SC 13D - KNOW LABS, INC. (0001074828) (Subject)

    10/25/23 7:27:11 PM ET
    $KNW
    Industrial Machinery/Components
    Industrials

    SEC Form SC 13D/A filed by Know Labs Inc. (Amendment)

    SC 13D/A - KNOW LABS, INC. (0001074828) (Subject)

    10/19/23 6:32:18 AM ET
    $KNW
    Industrial Machinery/Components
    Industrials